Boston Scientific Corporation (NYSE:BSX) EVP Timothy A. Pratt sold 11,061 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $29.24, for a total transaction of $323,423.64. Following the completion of the sale, the executive vice president now owns 174,681 shares of the company’s stock, valued at approximately $5,107,672.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Boston Scientific Corporation (NYSE BSX) traded up 1.03% during midday trading on Monday, hitting $29.47. The stock had a trading volume of 5,908,798 shares. The stock has a market capitalization of $40.44 billion, a PE ratio of 52.72 and a beta of 1.09. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $29.47. The stock’s 50-day moving average is $27.39 and its 200-day moving average is $26.61.

Boston Scientific Corporation (NYSE:BSX) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.01. The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $0.27 earnings per share. On average, equities research analysts anticipate that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Boston Scientific Corporation (BSX) EVP Sells $323,423.64 in Stock” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/02/boston-scientific-corporation-bsx-evp-sells-323423-64-in-stock.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Swiss National Bank lifted its stake in Boston Scientific Corporation by 2.9% during the 2nd quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock valued at $154,814,000 after acquiring an additional 156,800 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Boston Scientific Corporation by 10.5% in the 2nd quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock worth $253,854,000 after acquiring an additional 867,983 shares in the last quarter. Koch Industries Inc. bought a new stake in shares of Boston Scientific Corporation in the 1st quarter worth $307,000. Los Angeles Capital Management & Equity Research Inc. grew its stake in shares of Boston Scientific Corporation by 35,016.2% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock worth $84,337,000 after acquiring an additional 3,033,800 shares in the last quarter. Finally, Bellevue Group AG grew its stake in shares of Boston Scientific Corporation by 4.0% in the 1st quarter. Bellevue Group AG now owns 572,000 shares of the medical equipment provider’s stock worth $14,226,000 after acquiring an additional 22,000 shares in the last quarter. 90.44% of the stock is owned by institutional investors and hedge funds.

BSX has been the topic of several research analyst reports. BidaskClub downgraded shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Saturday, August 26th. Needham & Company LLC upped their price target on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 22nd. Royal Bank Of Canada reiterated a “buy” rating and issued a $31.00 price target on shares of Boston Scientific Corporation in a report on Friday, September 1st. Stifel Nicolaus reissued a “buy” rating and set a $32.00 price objective on shares of Boston Scientific Corporation in a research report on Sunday, July 30th. Finally, Zacks Investment Research downgraded shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Boston Scientific Corporation currently has a consensus rating of “Buy” and a consensus price target of $30.12.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.